| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A note on estimating local recurrence rates inclinical trials on the treatment of breast cancer
|
Gabi Schulgen
|
|
1998
|
49 |
1 |
p. 87-91
5 p.
|
article
|
| 2 |
A note on estimating local recurrence rates in clinical trials on the treatment of breast cancer
|
Schulgen, Gabi
|
|
1998
|
49 |
1 |
p. 87-91
|
article
|
| 3 |
Aromatase expression in the human breast
|
Angela Brodie
|
|
1998
|
49 |
1 |
p. S85-S91
7 p.
|
article
|
| 4 |
Aromatase expression in the human breast
|
Brodie, Angela
|
|
1998
|
49 |
1 |
p. S85-S91
|
article
|
| 5 |
Biochemical control of breast aromatase
|
A. Singh
|
|
1998
|
49 |
1 |
p. S9-S14
6 p.
|
article
|
| 6 |
Biochemical control of breast aromatase
|
Singh, A.
|
|
1998
|
49 |
1 |
p. S9-S14
|
article
|
| 7 |
Breast carcinoma in women under the age of50: Relationship between p53 immunostaining, tumour grade, andaxillary lymph node status
|
R. Pratap
|
|
1998
|
49 |
1 |
p. 35-39
5 p.
|
article
|
| 8 |
Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status
|
Pratap, R.
|
|
1998
|
49 |
1 |
p. 35-39
|
article
|
| 9 |
Clinical importance of intratumoral aromatase
|
Miller, W.R.
|
|
1998
|
49 |
1 |
p. S27-S32
|
article
|
| 10 |
Comparison of biochemical aromatase activity with aromataseimmunhistochemistry in human breast carcinomas
|
K.C. Shenton
|
|
1998
|
49 |
1 |
p. S101-S107
7 p.
|
article
|
| 11 |
Comparison of biochemical aromatase activity with aromatase immunhistochemistry in human breast carcinomas
|
Shenton, K.C.
|
|
1998
|
49 |
1 |
p. S101-S107
|
article
|
| 12 |
Demonstration of aromatase activity and its regulation inbreast tumor and benign breast fibroblasts
|
R.J. Santen
|
|
1998
|
49 |
1 |
p. S93-S99
7 p.
|
article
|
| 13 |
Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts
|
Santen, R.J.
|
|
1998
|
49 |
1 |
p. S93-S99
|
article
|
| 14 |
Determinants of tissue estradiol levels and biologic responsivenessin breast tumors
|
Wei Yue
|
|
1998
|
49 |
1 |
p. S1-S7
7 p.
|
article
|
| 15 |
Determinants of tissue estradiol levels and biologic responsiveness in breast tumors
|
Yue, Wei
|
|
1998
|
49 |
1 |
p. S1-S7
|
article
|
| 16 |
Diagnostic value of contrast-enhanced computed tomographyfor diagnosing the intraductal component of breast cancer
|
Sadako Akashi-Tanaka
|
|
1998
|
49 |
1 |
p. 79-86
8 p.
|
article
|
| 17 |
Diagnostic value of contrast-enhanced computed tomography for diagnosing the intraductal component of breast cancer
|
Akashi-Tanaka, Sadako
|
|
1998
|
49 |
1 |
p. 79-86
|
article
|
| 18 |
Direct comparisons of adjuvant endocrine therapy, chemotherapy, andchemoendocrine therapy for operable breast cancer patients stratifiedby estrogen receptor and menopausal status
|
Yasuo Nomura
|
|
1998
|
49 |
1 |
p. 51-60
10 p.
|
article
|
| 19 |
Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status
|
Nomura, Yasuo
|
|
1998
|
49 |
1 |
p. 51-60
|
article
|
| 20 |
Discussion
|
|
|
1998
|
49 |
1 |
p. S73-S77
5 p.
|
article
|
| 21 |
Discussion
|
|
|
1998
|
49 |
1 |
p. S33-S37
5 p.
|
article
|
| 22 |
Discussion
|
|
|
1998
|
49 |
1 |
p. S33-S37
|
article
|
| 23 |
Discussion
|
|
|
1998
|
49 |
1 |
p. S73-S77
|
article
|
| 24 |
Dr. Richard Santens editorial changes to discussion followingthe Friday morning 11 July 1997 session Immunochemicalapproaches to assessing intratumoral aromatase
|
|
|
1998
|
49 |
1 |
p. S109-S120
7 p.
|
article
|
| 25 |
Dr. Richard Santen's editorial changes to discussion following the Friday morning 11 July 1997 session 'Immunochemical approaches to assessing intratumoral aromatase'
|
|
|
1998
|
49 |
1 |
p. S109-S120
|
article
|
| 26 |
Fadrozole and letrozole in advanced breast cancer: Clinicaland biochemical effects
|
Ian E. Smith
|
|
1998
|
49 |
1 |
p. S67-S71
5 p.
|
article
|
| 27 |
Fadrozole and letrozole in advanced breast cancer: Clinical and biochemical effects
|
Smith, Ian E.
|
|
1998
|
49 |
1 |
p. S67-S71
|
article
|
| 28 |
Immunolocalization of aromatase in human breast disorders usingdifferent antibodies
|
Hironobu Sasano
|
|
1998
|
49 |
1 |
p. S79-S84
6 p.
|
article
|
| 29 |
Immunolocalization of aromatase in human breast disorders using different antibodies
|
Sasano, Hironobu
|
|
1998
|
49 |
1 |
p. S79-S84
|
article
|
| 30 |
Intratumoral aromatase model: The effects of letrozole (CGS20267)
|
Angela Brodie
|
|
1998
|
49 |
1 |
p. S23-S26
4 p.
|
article
|
| 31 |
Intratumoral aromatase model: The effects of letrozole (CGS 20267)
|
Brodie, Angela
|
|
1998
|
49 |
1 |
p. S23-S26
|
article
|
| 32 |
Molecular analysis of aberrant expression of aromatase inbreast cancer tissues
|
Nobuhiro Harada
|
|
1998
|
49 |
1 |
p. S15-S21
7 p.
|
article
|
| 33 |
Molecular analysis of aberrant expression of aromatase in breast cancer tissues
|
Harada, Nobuhiro
|
|
1998
|
49 |
1 |
p. S15-S21
|
article
|
| 34 |
Outcome of treatment for ipsilateral breast tumor recurrencein early-stage breast cancer
|
Kristina Dalberg
|
|
1998
|
49 |
1 |
p. 69-78
10 p.
|
article
|
| 35 |
Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer
|
Dalberg, Kristina
|
|
1998
|
49 |
1 |
p. 69-78
|
article
|
| 36 |
Pharmacological and clinical profile of anastrozole
|
Per E. Lønning
|
|
1998
|
49 |
1 |
p. S53-S57
5 p.
|
article
|
| 37 |
Pharmacological and clinical profile of anastrozole
|
Lønning, Per E.
|
|
1998
|
49 |
1 |
p. S53-S57
|
article
|
| 38 |
Pharmacological profiles of exemestane and formestane, steroidalaromatase inhibitors used for treatment of postmenopausal breast cancer
|
Per E. Lønning
|
|
1998
|
49 |
1 |
p. S45-S52
8 p.
|
article
|
| 39 |
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer
|
Lønning, Per E.
|
|
1998
|
49 |
1 |
p. S45-S52
|
article
|
| 40 |
Physiological and pathological changes of plasma urokinase-typeplasminogen activator, plasminogen activator inhibitor-1,and urokinase-type plasminogen activator receptor levelsin healthy females and breast cancer patients
|
Hyun Cheol Chung
|
|
1998
|
49 |
1 |
p. 41-50
10 p.
|
article
|
| 41 |
Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
|
Chung, Hyun Cheol
|
|
1998
|
49 |
1 |
p. 41-50
|
article
|
| 42 |
Pre-clinical and clinical review of vorozole, a newthird generation aromatase inhibitor
|
Paul E. Goss
|
|
1998
|
49 |
1 |
p. S59-S65
8 p.
|
article
|
| 43 |
Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor
|
Goss, Paul E.
|
|
1998
|
49 |
1 |
p. S59-S65
|
article
|
| 44 |
Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050)
|
Luo, Shouqi
|
|
1998
|
49 |
1 |
p. 1-11
|
article
|
| 45 |
Prognostic value of bone marrow biopsy in operablebreast cancer patients at the time of initialdiagnosis: Results of a 20-year median follow-up
|
K. Landys
|
|
1998
|
49 |
1 |
p. 27-33
7 p.
|
article
|
| 46 |
Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up
|
Landys, K.
|
|
1998
|
49 |
1 |
p. 27-33
|
article
|
| 47 |
The intracellular histamine antagonist,N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl, may potentiate doxorubicin in the treatmentof metastatic breast cancer: Results of a pilot study
|
Lorne J. Brandes
|
|
1998
|
49 |
1 |
p. 61-68
8 p.
|
article
|
| 48 |
The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine.HCl, may potentiate doxorubicin in the treatment of metastatic breast cancer: Results of a pilot study
|
Brandes, Lorne J.
|
|
1998
|
49 |
1 |
p. 61-68
|
article
|
| 49 |
Theoretical considerations for the ideal aromatase inhibitor
|
M. Dowsett
|
|
1998
|
49 |
1 |
p. S39-S44
7 p.
|
article
|
| 50 |
Theoretical considerations for the ideal aromatase inhibitor
|
Dowsett, M.
|
|
1998
|
49 |
1 |
p. S39-S44
|
article
|
| 51 |
The Susan G. Komen Breast Cancer Foundation brings national Race For The Cure® series to recordbreaking 86 cities in 1998
|
|
|
1998
|
49 |
1 |
p. 93-93
1 p.
|
article
|
| 52 |
The Susan G. Komen Breast Cancer Foundation brings national Race For The Cure® series to record–breaking 86 cities in 1998
|
|
|
1998
|
49 |
1 |
p. 93
|
article
|
| 53 |
Weekly paclitaxel-cisplatin administration with G-CSFsupport in advanced breast cancer. A phase II study
|
Giuseppe Frasci
|
|
1998
|
49 |
1 |
p. 13-26
14 p.
|
article
|
| 54 |
Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study
|
Frasci, Giuseppe
|
|
1998
|
49 |
1 |
p. 13-26
|
article
|
Journal description